Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation

NCT02719574 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

336

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Myeloid Leukemia
Acute Myelogenous Leukemia
Myelodysplastic Syndrome

Interventions

DRUG: FT-2102 (olutasidenib)
DRUG: Azacitidine
DRUG: Cytarabine

Sponsor

Forma Therapeutics, Inc.